Clinical Trials Directory

Trials / Suspended

SuspendedNCT06451835

Evaluation of Response to a Course of Repetitive Transcranial Magnetic Stimulation Using Vocal Biomarkers

Evaluation of Response to a Course of Repetitive Transcranial Magnetic Stimulation (rTMS) for the Treatment of Major Depressive Disorder Using Vocal Biomarkers

Status
Suspended
Phase
Study type
Observational
Enrollment
156 (estimated)
Sponsor
GCS CIPS · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Voice recordings taken prior to the start of repetitive transcranial magnetic stimulation (rTMS) therapy will be used to develop a predictive model of treatment response using machine learning for patients with major depressive disorders (MDD).

Detailed description

The objective of this study is to investigate whether voice biomarkers taken prior to the start of rTMS can predict the response to a 30-session course of rTMS in patients with MDD with good sensitivity and specificity. Patients who are prescribed rTMS to treat an episode of MDD at one of the nine participating centres will be invited to participate in the study. The protocol includes one inclusion visit and seven evaluation visits before, during, and after the course of rTMS. The rTMS course will last for six weeks, comprising of 30 sessions with five sessions per week. Prior to the commencement of the rTMS course, patients will need to complete several questionnaires. Before the first session, voice tests will be recorded using the Callyope application. Patients will answer questionnaires and assess voice tests weekly and after the final rTMS session to track the progression of depressive symptoms.

Conditions

Interventions

TypeNameDescription
DEVICErepetitive transcranial magnetic stimulation (rTMS)rTMS will be applied 5 days out of 7 for 6 weeks, for a total of 30 sessions. The area stimulated will be the left dorsolateral prefrontal cortex, at a frequency of 10 Hz, at 110% of motor threshold for approximately 20 minutes (i.e. 3,000 stimulations per session).

Timeline

Start date
2024-06-13
Primary completion
2025-04-15
Completion
2025-06-15
First posted
2024-06-11
Last updated
2025-03-12

Locations

9 sites across 1 country: France

Source: ClinicalTrials.gov record NCT06451835. Inclusion in this directory is not an endorsement.